With the entrance of RET inhibitor TPX-0046 into P1/2 last November, fast moving Turning Point Therapeutics now has a full slate of 3 clinical candidates. Soon, another ALK inhibitor is expected to join the fray. Pipeline: The pivotal repotrectinib studies in ROS1 and TRK are ongoing with interim results from some registrational cohorts expected during […]
Initiating: Turning Point Therapeutics
San Diego based Turning Point Therapeutics is an oncology focused biotech that completed a successful IPO in April this year, raising about $190M with pricing at $18/sh. As the stock continued to climb, TPTX quickly filed for a secondary on September 3rd, adding another $200M to its cash hoard. The company is now very well […]
ARQL- Quick Take
I have been following Arqule off and on for quite some time. The company has been reborn after so many lost years pursuing its failed MET inhibitor ARQ 197. Hopes are high for lead asset ARQ 531, a competitive inhibitor of BTK. Arqule also has a pipeline of 2 AKT inhibitors and an out-licensed FGFR […]
August 16th Biotech Update
So far the week is ending on a positive note but it is early but not surprising that we see some sort of bounce in the market. I sort of wonder how the trading ends the day as it will send a stronger signal than how trading starts. We have seen a lot of macro […]
June 17 Biotech Update
It is a good start to the week with merger Monday coming back the sector albeit with names we were not expecting. The XBI has been in a nice tight range and while we are still in that range this morning, I would look for a breakout about $84. I am not exactly calling for […]
January 7 Biotech Update
This is one hell of a start for biotechs this year. M&A and good data are back. Of course, there is a bias in JPM week to present good news early, so I would be surprised to see this rate of positive news to continue all week but this is certainly a great start and […]
November 29 Biotech Update
We are at an interesting place for the sector. The XBI is approaching the upper end of the downtrend, which has been acting as resistance. I am not totally convinced that will be the case this time as the recent move lower did not form a lower low. That hints that we could be leaving […]
November 28 Biotech Update
Yesterday as a bad day for the sector as it was red with a positive broader market backdrop. To be fair it was a rather odd day in the sector as the large caps also grossly outperformed the SMID space, which was held down by some large losses. I am not quite willing to see […]
October 22 Biotech Update
This should not be week of no news as we have the ESMO data to digest as well as a number of large cap earnings to work through. Unless there is some massive move in the market, it is hard to imagine that the sector does not trade on the news as opposed to following […]
October 9 Biotech Update
It was certainly not a great start to the week and the sector really needs a turnaround Tuesday to pan out. Interestingly, the pharma and large cap bios did OK yesterday as perhaps a flight to safety trade. The IBB seems right at the bottom of its range and has the potential to find support […]
September 26 Biotech Update
Yesterday was a little odd. It was generally a good day for the sector but a lot of companies had very large ranges for no apparent reason and on no news. Usually you can see those swings at turning points but it seems odd to be happening essentially in the middle of a range bound […]
September 18 Biotech Update
The sector struggled yesterday and it still looks like testing the bottom on the range is possible. Perhaps the China tariffs news cleared the market a little and we might avoid that scenario. It remains to be seen but a green start today is nice to see but it would be better to see it […]
August 13 Biotech Update
The chop continues and I suspect this week will be no different. There is not any news to start the week that would excite or disappoint, which means the previous trend (of no trend) is the path of least resistance. It is interesting that no one even talks about M&A anymore as that was supposed […]
August 10th Biotech Update
While yesterday ended up being quite positive for the sector (in general), I am still not going to read too much into it and would not be surprised to see those gains disappear in the next couple days. My view remains a low volume chop to the sector until we get out of the summer […]
August 9th Biotech Update
The chop continues. I just do not see anything definitive in either direction and am coming around to the belief that we are not going to see anything definitive soon. I suspect we bounce between 113 and 120 on the IBB for a bit and then come the fall we see a break with volume […]
August 1 Biotech Update
The sector recovered a little yesterday from last week’s sell-off but ideally we would need to see the sector break into new highs. It seems highly likely that the sector tests the recent highs and the price action at that point is likely to be a strong signal of underlying strength. Given the fundamentals and […]
June 25 Biotech Update
This will be an interesting day to see if the breakout will be confirmed as real or confirmed as false. We are back testing the previous levels of resistance and without a bounce from these levels, then I doubt the sector can continue to move higher. The news this morning is not helping as there […]
June 4 Biotech Update
Despite the lack of any real thesis changing news, ASCO seemed to be fairly typical. There will be a couple of big winners but more losers as you have both bad data and data that was good but not good enough for inflated expectations. Given the dearth of major data, I wonder if there will […]
May 29 Biotech Update
You would think that after a long weekend there would be more news but it is a slow start to the week. Perhaps it is related to the upcoming ASCO conference. Unfortunately, it looks like macro might again grip the sector as another Euro based crisis has arisen with fears of an impending Italian crisis. […]
May 17 Biotech Update
Some interesting moves and data coming out of the ASCO abstracts. There are some questions answered with these abstracts, although more questions remain unanswered. I suspect that many of the morning moves in these stocks will be moderated by the end of the day as ultimately there is nothing thesis changing that can come out […]
